The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Business   »  Inovio Pharmaceuticals Inc.’s (INO) Stock: ...

Inovio Pharmaceuticals Inc.’s (INO) Stock: A 61.03% Annual Performance Rate

In the past week, INO stock has gone down by -13.61%, with a monthly decline of -11.57% and a quarterly plunge of -21.90%. The volatility ratio for the week is 6.30%, and the volatility levels for the last 30 days are 7.02% for Inovio Pharmaceuticals Inc. The simple moving average for the past 20 days is -11.02% for INO’s stock, with a -59.59% simple moving average for the past 200 days.

Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ: INO) Right Now?

and a 36-month beta value of 0.98. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price predicted for Inovio Pharmaceuticals Inc. (INO) by analysts is $0.50, which is $0.86 above the current market price. The public float for INO is 263.77M, and at present, short sellers hold a 6.33% of that float. On September 19, 2023, the average trading volume of INO was 4.84M shares.

INO) stock’s latest price update

The stock price of Inovio Pharmaceuticals Inc. (NASDAQ: INO) has dropped by -2.86 compared to previous close of 0.40. Despite this, the company has seen a fall of -13.61% in its stock price over the last five trading days. Seeking Alpha reported 2023-09-12 that Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea – President and Chief Executive Officer Conference Call Participants Li Chen – H.C.

INO Trading at -17.15% from the 50-Day Moving Average

After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.04% of loss for the given period.

Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 6.30%, as shares sank -11.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.45% lower at present.

During the last 5 trading sessions, INO fell by -13.19%, which changed the moving average for the period of 200-days by -80.76% in comparison to the 20-day moving average, which settled at $0.4364. In addition, Inovio Pharmaceuticals Inc. saw -74.97% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at INO starting from Zoth Lota S., who sale 5,700 shares at the price of $0.56 back on Jun 05. After this action, Zoth Lota S. now owns 52,716 shares of Inovio Pharmaceuticals Inc., valued at $3,192 using the latest closing price.

Weiner David B., the Director of Inovio Pharmaceuticals Inc., sale 5,833 shares at $1.15 during a trade that took place back on Mar 13, which means that Weiner David B. is holding 910,124 shares at $6,708 based on the most recent closing price.

Stock Fundamentals for INO

Current profitability levels for the company are sitting at:

  • -2672.64 for the present operating margin
  • +46.44 for the gross margin

The net margin for Inovio Pharmaceuticals Inc. stands at -2726.67. The total capital return value is set at -79.83, while invested capital returns managed to touch -82.09. Equity return is now at value -78.60, with -54.30 for asset returns.

Based on Inovio Pharmaceuticals Inc. (INO), the company’s capital structure generated 14.42 points at debt to equity in total, while total debt to capital is 12.61. Total debt to assets is 9.14, with long-term debt to equity ratio resting at 13.16. Finally, the long-term debt to capital ratio is 11.50.

When we switch over and look at the enterprise to sales, we see a ratio of -11.76, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 1.04 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.25.


To sum up, Inovio Pharmaceuticals Inc. (INO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.